Breaking News Instant updates and real-time market news.

BCRX

BioCryst

$6.15

(0.00%)

, IDRA

Idera Pharmaceuticals

$1.38

-0.01 (-0.72%)

16:57
07/10/18
07/10
16:57
07/10/18
16:57

BioCryst jumps, Idera falls after proposed merger terminated

BioCryst Pharmaceuticals (BCRX) announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals (IDRA) following the BioCryst stockholders' failure to approve the adoption of the merger agreement at the BioCryst Special Meeting of Stockholders held on Tuesday. BioCryst shares rallied over 9% after hours, following the announcement, while Idera shares dropped 7% after hours. BioCryst said it would reimburse Idera for $6M transaction-related expenses as a result of terminating the merger agreement.

BCRX

BioCryst

$6.15

(0.00%)

IDRA

Idera Pharmaceuticals

$1.38

-0.01 (-0.72%)

  • 10

    Jul

  • 10

    Jul

BCRX BioCryst
$6.15

(0.00%)

01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
BioCryst upgraded to Outperform from Sector Perform at RBC Capital
01/02/18
RBCM
01/02/18
UPGRADE
Target $8
RBCM
Outperform
BioCryst upgraded to Outperform at RBC Capital on BCX7353 performance
As reported earlier, RBC Capital analyst Brian Abrahams upgraded BioCryst to Outperform from Sector Perform and raised his price target to $8 from $6. Abrahams says the lead drug BCX7353 showed a clear reduction in hereditary angioedema attacks in its phase 2 study, while its lack of dose dependence is "legitimately explainable by misidentification of GI side effects at the higher doses". The analyst adds that the recent FDA precedent also implies a "relatively low bar for approvals of drugs to treat rare, potentially fatal diseases".
06/22/18
GHSC
06/22/18
INITIATION
GHSC
Neutral
BioCryst initiated with a Neutral at Seaport Global
Seaport Global initiated BioCryst (BCRX) with a Neutral due to uncertainty on its proposed merger with Idera Pharmaceuticals (IDRA) and views risk/reward as balanced.
06/22/18
06/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunlands Online (STG) initiated with an Outperform at Credit Suisse. 2. Micron (MU) initiated with a Buy at Benchmark. 3. Interpace Diagnostics (IDXG) initiated with a Buy at Ladenburg. 4. Alteryx (AYX) initiated with an Outperform at Oppenheimer. 5. BioCryst (BCRX) initiated with a Neutral at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
IDRA Idera Pharmaceuticals
$1.38

-0.01 (-0.72%)

11/09/17
HCWC
11/09/17
INITIATION
Target $4
HCWC
Buy
Idera Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Idera Pharmaceuticals with a Buy rating and $4 price target. The company's two lead products have "significant potential in the fast growing immunotherapy market," the analyst contends.
11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
PIPR
11/09/17
NO CHANGE
Target $4
PIPR
Overweight
Piper reiterates Overweight rating on Idera after IMO-2125 trial update
After Idera Pharmaceuticals reported a 5th unconfirmed RECIST response in its ongoing IMO-2125 plus Yervoy combo trial in PD-1 refractory metastatic melanoma, bringing the ORR to 50%, Piper Jaffray analyst Edward Tenthoff reiterated his Overweight rating and $4 price target on the stock, which is up 15% to $2.03 in midday trading.
06/13/18
JMPS
06/13/18
NO CHANGE
Target $4
JMPS
Outperform
Idera Pharmaceuticals price target lowered to $4 from $8 at JMP Securities
JMP Securities analyst Konstantinos Aprilakis lowered his price target on Idera Pharmaceuticals to $4 from $8 after the company's Phase 2 trial of IMO-8400 in the dermatomyositis setting did not meet its primary endpoint. While he views this latest development for IMO-8400 as disappointing, he reminds investors of the positive tilsotolimod data recently presented at ASCO and still thinks tilsotolimod plus ipilimumab has the potential for a favorable competitive profile in the anti PD-1 refractory melanoma setting. Aprilakis keeps an Outperform rating on Idera shares.

TODAY'S FREE FLY STORIES

EBAY

eBay

$28.73

-2.83 (-8.97%)

07:42
10/22/18
10/22
07:42
10/22/18
07:42
Downgrade
eBay rating change  »

eBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 03

    Mar

HD

Home Depot

$179.87

-0.56 (-0.31%)

07:40
10/22/18
10/22
07:40
10/22/18
07:40
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

, MRK

Merck

$72.34

0.12 (0.17%)

07:39
10/22/18
10/22
07:39
10/22/18
07:39
Downgrade
Bristol-Myers, Merck rating change  »

Citi sees Merck showing…

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 11

    Jan

  • 16

    Feb

  • 20

    May

XYL

Xylem

$69.26

-0.63 (-0.90%)

07:39
10/22/18
10/22
07:39
10/22/18
07:39
Recommendations
Xylem analyst commentary  »

Need better risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

KMB

Kimberly-Clark

$110.30

0.79 (0.72%)

07:38
10/22/18
10/22
07:38
10/22/18
07:38
Hot Stocks
Kimberly-Clark sees FY18 share repurchases $800M »

Third quarter 2018 share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HOG

Harley-Davidson

$39.56

-0.81 (-2.01%)

07:38
10/22/18
10/22
07:38
10/22/18
07:38
Recommendations
Harley-Davidson analyst commentary  »

Harley-Davidson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

EWBC

East West Bancorp

$53.86

0.1 (0.19%)

07:37
10/22/18
10/22
07:37
10/22/18
07:37
Upgrade
East West Bancorp rating change  »

East West Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 27

    Nov

  • 04

    Dec

STBZ

State Bank Financial

$25.44

-1.02 (-3.85%)

07:37
10/22/18
10/22
07:37
10/22/18
07:37
Earnings
State Bank Financial reports Q3 EPS 46c, consensus 57c »

Reports Q3 Tier 1 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$77.74

-9.33 (-10.72%)

07:37
10/22/18
10/22
07:37
10/22/18
07:37
Recommendations
VF Corp. analyst commentary  »

VF Corp. weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$110.30

0.79 (0.72%)

07:37
10/22/18
10/22
07:37
10/22/18
07:37
Hot Stocks
Kimberly-Clark provides update to 2018 guidance »

The company updated the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TM

Toyota

$116.34

-0.34 (-0.29%)

07:36
10/22/18
10/22
07:36
10/22/18
07:36
Upgrade
Toyota rating change  »

Toyota upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CMG

Chipotle

$429.09

-2.63 (-0.61%)

07:35
10/22/18
10/22
07:35
10/22/18
07:35
Recommendations
Chipotle analyst commentary  »

Chipotle customer trends…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

KMB

Kimberly-Clark

$110.30

0.79 (0.72%)

07:35
10/22/18
10/22
07:35
10/22/18
07:35
Hot Stocks
Kimberly-Clark CEO says profitability impacted by commodity, currency headwinds »

Chairman and CEO Thomas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BAC

Bank of America

$28.31

0.05 (0.18%)

, AAL

American Airlines

$32.05

(0.00%)

07:35
10/22/18
10/22
07:35
10/22/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BAC

Bank of America

$28.31

0.05 (0.18%)

AAL

American Airlines

$32.05

(0.00%)

CTL

CenturyLink

$22.00

0.96 (4.56%)

HLT

Hilton

$70.66

-1.42 (-1.97%)

GRPN

Groupon

$3.22

-0.29 (-8.26%)

TER

Teradyne

$32.76

-0.02 (-0.06%)

FOSL

Fossil

$18.67

-0.46 (-2.40%)

ECHO

Echo Global

$25.91

0.665 (2.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

XELA

Exela Technologies

$6.33

-0.07 (-1.09%)

07:34
10/22/18
10/22
07:34
10/22/18
07:34
Initiation
Exela Technologies initiated  »

Exela Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 26

    Nov

ZLAB

Zai Lab

$16.33

-0.05 (-0.31%)

07:34
10/22/18
10/22
07:34
10/22/18
07:34
Hot Stocks
Zai Lab announces approval of Zejula for patients with relapsed ovarian cancer »

Zai Lab Limited announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$124.96

0.81 (0.65%)

07:34
10/22/18
10/22
07:34
10/22/18
07:34
Hot Stocks
BeiGene announces preliminary data from pamiparib study at ESMO »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

INTC

Intel

$43.98

-1 (-2.22%)

07:34
10/22/18
10/22
07:34
10/22/18
07:34
Upgrade
Tactical call or not, Nomura upgrades Intel to Buy with $50 target »

Nomura Instinet analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

KMB

Kimberly-Clark

$110.30

0.79 (0.72%)

07:33
10/22/18
10/22
07:33
10/22/18
07:33
Hot Stocks
Kimberly-Clark names Michael Hsu as CEO, succeeding Thomas Falk »

Kimberly-Clark announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

RMED

Ra Medical Systems

$13.50

1.59 (13.35%)

07:33
10/22/18
10/22
07:33
10/22/18
07:33
Initiation
Ra Medical Systems initiated  »

Ra Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLXE

KLX Energy

$32.22

0.27 (0.85%)

07:33
10/22/18
10/22
07:33
10/22/18
07:33
Hot Stocks
KLX Energy to acquire Motley Services for total consideration of $148M »

KLX Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$45.37

-1.09 (-2.35%)

07:32
10/22/18
10/22
07:32
10/22/18
07:32
Upgrade
Crown Holdings rating change  »

Crown Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCR

Novocure

$42.69

-2.37 (-5.26%)

07:32
10/22/18
10/22
07:32
10/22/18
07:32
Hot Stocks
Novocure announces publication of results of PANOVA phase 2 pilot trial »

Novocure announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

VIOT

Viomi Technology

$8.11

-0.21 (-2.52%)

07:32
10/22/18
10/22
07:32
10/22/18
07:32
Initiation
Viomi Technology initiated  »

Viomi Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$110.30

0.79 (0.72%)

07:32
10/22/18
10/22
07:32
10/22/18
07:32
Hot Stocks
Breaking Hot Stocks news story on Kimberly-Clark »

Kimberly-Clark names…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.